Oncotarget

Clinical Research Papers:

Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study

Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang and Hai-Liang Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:97613-97622. https://doi.org/10.18632/oncotarget.18811

Metrics: PDF 738 views  |   HTML 1287 views  |   ?  


Abstract

Lin Zheng1, Chen-Yang Guo1, Cheng-Shi Chen1, Jin-Cheng Xiao1, Hong-Tao Hu1, Hong-Tao Cheng1, Deng-Wei Zong1, Li Jiang1 and Hai-Liang Li1

1Department of Radiology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou 450008, China

Correspondence to:

Hai-Liang Li, email: cjr.lihailiang@vip.163.com

Keywords: lipiodol deposition, hepatocellular carcinoma, TACE, sorafenib, overall survival

Received: August 02, 2016     Accepted: June 08, 2017     Published: June 29, 2017

ABSTRACT

Objective: Though synergy of sorafenib and transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) is well discussed in previous reports, association of lipiodol retention by sorafenib addition to TACE with the survival outcomes remain elusive. Therefore, we studied the impact of sorafenib addition to TACE on survival outcomes mediated by lipiodol retention.

Materials and Methods: This is a long-term, retrospective, single-center study using medical records of patients diagnosed with HCC at the Department of Interventional Radiology of Zhengzhou University Affiliated Cancer Hospital (China) between April 2004 and March 2012.

Results: Lipiodol deposition of > 50% was significantly increased in TACE + sorafenib group (70.87%) compared to TACE alone group (45.11%) (P = 0.0001). Significant increase in lipiodol deposition with sorafenib treatment was observed compared to TACE alone group (OR = 0.449, P = 0.041). The median overall survival in TACE + sorafenib and TACE alone groups were 38 months [95% CI = 9.772–56.228] and 31 months [95% CI = 21.855–40.145] respectively. Also, the hazard of death was comparatively greater in TACE alone group than TACE + sorafenib group [HR = 1.071]. Response rate to the therapy significantly increased after sorafenib administration to TACE patients, [compared to TACE alone treatment [69/103 (66.99%)] vs 55/133 (41.35%)], P = 0.0001.

Conclusions: Lipiodol deposition is significantly increased upon sorafenib addition after TACE. However, there was no significant impact of lipiodol deposition on the survival benefits exerted by the synergistic combination and hence, future prospective trails are warranted to validate the findings of this study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18811